Borrowing from principles used in rheumatoid arthritis and psoriasis management, current guidelines recommend that the overarching goal in the treatment of patients with psoriasis and psoriatic arthritis be the achievement of remission or minimal disease activity in a treat-to-target approach. To aid in achieving this goal, a wide range of new therapies with good clinical efficacy and safety have been, and continue to be, developed. There is a need for clinician education to improve the knowledge of the efficacy and safety profiles of these new and emerging agents, as well as how to approach treatment selection for patients with comorbidities.